MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Anthony S. Crisci, Esq., CPA has joined the Company as the General Manager, Chief Compliance Officer & Corporate Counsel for all of NuGenerex’s distribution efforts, including its newly acquired eight (8) pharmacies and laboratory from Veneto Holdings, L.L.C., to lead the Company in building an end-to-end solution for pharmacy and health management services. Mr. Crisci, a member of the New York and New Jersey Bar associations, as well as a licensed CPA, has built a stellar career as a business legal executive across a number of regulated industries. Recently, he has been General Counsel, COO, CFO, and Controller for a publicly traded holding company, specializing in financial services and technology software companies. Previously, he served as Corporate Counsel for a major health system with $1 Billion in annual revenues, and General Counsel for a National Pharmacy Benefit Management Company that includes mail and specialty drug dispensing. Mr. Crisci brings a broad range of capabilities with his legal, business, financial, and regulatory background, and his expertise will be deployed to execute on the Company’s strategic objectives, including mergers & acquisitions, joint venture and development agreements, in-licensing and out-licensing agreements, and most importantly, long term supply and distributorship agreements for nation-wide pharmacy, laboratory, and medical management services.
“We are extremely excited to have an executive with Anthony’s skill set and experience overseeing business, accounting, and legal matters for NuGenerex’s distribution enterprise, including NuGenerex Distribution Solutions,” said Terry Thompson, COO of Generex; “With his experience and extensive background in corporate affairs, Anthony will implement the corporate strategy to build a next-generation life sciences company focused on delivery of end-to-end patient solutions. His unwavering focus on building successful healthcare businesses while maintaining strict legal and regulatory compliance will be essential for our ongoing success.”
Mr. Crisci added: “I want to thank Joe Moscato, CEO of Generex, for this incredible opportunity to work with such a skilled and professional group of people. With Terry Thompson (COO) and Mark Fletcher (GC) as my sounding board and Joe Moscato (CEO) leading the Company, along with the other dedicated members of Generex, we have the recipe for success.”
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.